ReviewJournal of neural transmission (Vienna, Austria : 1996)2009
Pharmacogenetics of anxiolytic drugs.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Therapygenetics: anterior cingulate cortex-amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia.Journal of neural transmission (Vienna, Austria : 1996) · 2015Trial
- Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.The pharmacogenomics journal · 2013Trial
- Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.The pharmacogenomics journal · 2013Trial
- CYP2D6 gene polymorphisms influence postoperative pain sensitivity and drug response in lung cancer surgery.International journal of clinical and experimental pathology · 2026Article
- Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms.Genes · 2023Review
- The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.Genes · 2023Review
- Personalized Management and Treatment of Alzheimer's Disease.Life (Basel, Switzerland) · 2022Review
- Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report.BMC psychiatry · 2022Article
- Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.International journal of environmental research and public health · 2021Review
- The beneficial effects of physical exercise in the brain and related pathophysiological mechanisms in neurodegenerative diseases.Laboratory investigation; a journal of technical methods and pathology · 2019Review
- Hiccup Due to Aripiprazole Plus Methylphenidate Treatment in an Adolescent with Attention Deficit and Hyperactivity Disorder and Conduct Disorder: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2017Article
- Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.Psychiatry research · 2017Article
- Clinical applications of CYP genotyping in psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- Exercise benefits brain function: the monoamine connection.Brain sciences · 2013Article
- Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Pharmacogenomics · 2012Review
- Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder.Neuroscience letters · 2011Article
- Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety.The Journal of pharmacology and experimental therapeutics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute and chronic anxiety represents the core symptoms in anxiety disorders. Anxiolytic pharmacological treatment mainly consists in administration of benzodiazepines and antidepressants. Whereas benzodiazepines show little, antidepressants show a relative large interindividual variability in terms of drug response where about one-third of patients do not respond at all. With no meaningful predictors available, there is increasing hope that genetics can help in adding important pieces of information in order to avoid lengthy drug trials and/or to avoid side effects. However, only few studies have been conducted with antidepressants and benzodiazepines in anxiety disorders. Similar to studies in major depression, some significant findings indicate that presence of the long allele of the serotonin transporter (5-HTT) gene is associated with favorable response. Other significant findings pointed to the serotonin 2A (5-HT2A) receptor and to the tryptophan hydroxylase (TPH1) genes. To date, the most promising strategy in clinical practice appears to incorporate testing of functional CYP450 gene variants (CYP1A2, CYP3A4, CYPD26 and CYP2C19) to avoid over- or under-dosing in poor or rapid metabolizers, respectively. As research progresses, it is likely that further gene variants will be detected that in conjunction with clinical variables will lead to algorithms allowing for individualized anxiolytic drug treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.